First Hepatitis C World Community Advisory Board Meeting

Provided by ACTUP-BASEL

Sunday 23 February 2014
All the versions of this article: [English]

February 22 – 25 2014 / Bangkok, Thailand

Organized by Treatment Action Group (TAG) with support from Asia Pacific Network of People Living with HIV/AIDS (APN+) and funded by TAG, the Open Society Institute, the World Health Organization, Médecins du Monde, Global Network of People living with HIV and AIDS Fonds. This first meeting will gather 40 international activists and should be the occasion to strategize together in order to increase HCV treatment access by addressing the following key issues: intellectual property, people who inject drugs (PWID), men who have sex with men (MSM), HCV DAA patent update and strategies for access, experiences of Asia and EECA CAB pharma negotiations, etc. In a second phase, activists will hold meetings with different originator and generic companies in order to clarify and make transparent the plans and policies of these companies.

AGENDA

Saturday, Feb. 22 (Day 1)

8:45 – 9:45 Welcome (K.Kaplan, TAG and S. Phurailatpam, APN+)
Participant introductions
Review meeting objectives, format, and expectations
Discuss meeting report

9:45 - 11:15 Basic DAA Literacy Training (T. Swan, TAG)

11:15 - 11:30 Coffee Break

11:30 - 12:30 Introduction to biosimilars (E.Torreele, A. Momen,OSF)

12:30 - 1:30 Lunch

1:30 - 3:00 Strategizing for HCV treatment access: addressing key intellectual property issues
Strategies for access to HCV treatments (P. Londeix, Act Up-­Basel)
Addressing key IP issues (P.Londeix, Act Up‐Basel, K. Bhardwaj, India)

3:00 - 3:15 Coffee Break

3:15 - 5:00 Patent opposition discussion

5:00 - 5:30 Wrap up

Sunday, Feb. 23rd (Day 2)

9:00 - 0:30 Key populations: people who inject drugs (PWID), men who have sex with men (MSM)
HCV situation, issues and access barriers for PWID (J.Byrne, INPUD)
HCV situation, issues and access barriers for MSM (N.Metheny, MSM-GF)

10:30 - 11:30 HCV DAA patent update and strategies for access (T. Amin, I-MAK)

11:30 - 11:45 Coffee Break

11:45 - 1:00 Pharmaceutical company approaches to HCV treatment access (P. Cawthorne, MSF; S. Collins, HIV i-base)
Pricing policies
Registration practices,
Voluntary licensing (Pros and Cons)

1:00 - 2:00 Lunch

2:00 - 3:00 Experiences of Asia and EECA CAB pharma negotiations (S. Phurailatpam, S. Golovin, ITPC-Ru)

3:00 - 4:30 Drug company meeting logistics (T. Swan, S. Collins)
Specific company introductions/background
Principles, format of Pharma and generic/biosimilar producer meetings
Statements, messages, demands (including meeting press release review)

4:30 - 4:45 Coffee Break

4:45 - 6:00 Drug company meeting logistics (continued)

6:00 - 6:30 Q&A, wrap‐up (Facilitator: K. Kaplan)

Monday, February 24th (Day 3) – Originator Companies

9:00-­‐11:00 Meeting with BMS

11:00 - 11:15 Coffee Break

11:15 - 1:15 Meeting with Abbvie

1:15 - 2:15 Lunch

2:00 - 4:00 Meeting with Janssen

4:15 - 4:30 Coffee Break

4:30 - 6:30 Meeting with Merck

Tuesday, February 25th (Day 4) – Originator Companies

9:00 - 11:00 Meeting with Roche

11:00 - 11:15 Coffee Break

11:15 - 12:00 Advocacy discussion

12:00 - 1:00 Lunch

1:00 - 4:00 Meeting with Gilead

4:00 - 5:00 Meeting with generic company

CLOSING

Source